AU2009219154A1 - Protein kinase modulators - Google Patents

Protein kinase modulators Download PDF

Info

Publication number
AU2009219154A1
AU2009219154A1 AU2009219154A AU2009219154A AU2009219154A1 AU 2009219154 A1 AU2009219154 A1 AU 2009219154A1 AU 2009219154 A AU2009219154 A AU 2009219154A AU 2009219154 A AU2009219154 A AU 2009219154A AU 2009219154 A1 AU2009219154 A1 AU 2009219154A1
Authority
AU
Australia
Prior art keywords
pct
optionally substituted
compound
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009219154A
Other languages
English (en)
Inventor
Peter C. Chua
Mustapha Haddach
Johnny Yasuo Nagasawa
Fabrice Pierre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of AU2009219154A1 publication Critical patent/AU2009219154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2009219154A 2008-02-29 2009-02-28 Protein kinase modulators Abandoned AU2009219154A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6784508P 2008-02-29 2008-02-29
US61/067,845 2008-02-29
US10390808P 2008-10-08 2008-10-08
US61/103,908 2008-10-08
PCT/US2009/035609 WO2009108912A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Publications (1)

Publication Number Publication Date
AU2009219154A1 true AU2009219154A1 (en) 2009-09-03

Family

ID=41016490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009219154A Abandoned AU2009219154A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Country Status (8)

Country Link
US (2) US8168651B2 (https=)
EP (1) EP2259678A4 (https=)
JP (1) JP2011515337A (https=)
CN (1) CN102036561A (https=)
AU (1) AU2009219154A1 (https=)
CA (1) CA2716755A1 (https=)
MX (1) MX2010009445A (https=)
WO (1) WO2009108912A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US20110065698A1 (en) * 2009-08-26 2011-03-17 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
MX2012002480A (es) * 2009-09-03 2012-03-26 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
BR112012005957A2 (pt) * 2009-09-16 2019-09-24 Cylene Pharmaceuticals Inc compostos tricíclicos e usos farmacêuticos dos mesmos
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
HUE045270T2 (hu) * 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
RS56494B1 (sr) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11584763B2 (en) 2017-12-22 2023-02-21 Hibercell, Inc. Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
US11332476B2 (en) * 2018-04-03 2022-05-17 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
EA202191349A1 (ru) * 2018-11-15 2021-08-10 Ниппон Синяку Ко., Лтд. 1,3,4-оксадиазолон и фармацевтический препарат
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
GB201902759D0 (en) 2019-02-28 2019-04-17 Benevolentai Bio Ltd Compositions and uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN113444085B (zh) * 2020-03-26 2022-04-08 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
AU2021249224A1 (en) * 2020-03-30 2022-12-01 Senhwa Biosciences, Inc. Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
AU2021360636A1 (en) * 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2023225586A2 (en) * 2022-05-19 2023-11-23 4M Therapeutics Inc. Novel azaphenantrhene derivatives as inhibitors of glycogen synthase kinase 3 for therapeutic use
KR20250140599A (ko) * 2023-02-03 2025-09-25 미라티 테라퓨틱스, 인크. 치환된 트리시클릭 화합물
US11987581B1 (en) 2023-12-19 2024-05-21 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors
US12024518B1 (en) 2023-12-20 2024-07-02 King Faisal University Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US11964974B1 (en) 2024-01-08 2024-04-23 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
US7589101B2 (en) * 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2009519336A (ja) * 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
WO2008042282A2 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Also Published As

Publication number Publication date
US20120208792A1 (en) 2012-08-16
EP2259678A1 (en) 2010-12-15
US8168651B2 (en) 2012-05-01
US20090239859A1 (en) 2009-09-24
JP2011515337A (ja) 2011-05-19
WO2009108912A1 (en) 2009-09-03
MX2010009445A (es) 2011-05-25
CA2716755A1 (en) 2009-09-03
CN102036561A (zh) 2011-04-27
EP2259678A4 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
US8168651B2 (en) Protein kinase modulators
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
JP5770102B2 (ja) 複素環化合物と使用方法
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
ES2477221T3 (es) Compuestos que contienen nitrógeno y sus composiciones farmacéuticas para el tratamiento de la fibrilaci�n auricular
US8536180B2 (en) Pyrimidine inhibitors of kinase activity
US8354422B2 (en) Pyrimidine inhibitors of kinase activity
US9181239B2 (en) Pyridopyrimidinone inhibitors of kinases
CA2943815A1 (en) Substituted indole mcl-1 inhibitors
US8486933B2 (en) Pyrimidine inhibitors of kinase activity
AU2014244263A1 (en) CDK9 kinase inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period